씨티씨바이오

060590KOSDAQ의약품 제조업

45.8 / 100

Reference Date: 2026-06-10

Financial Score11.5 / 40

News Sentiment21.3 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE is above the industry average but the high debt ratio poses financial risk. Declined 12.8% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

CTC Bio operates in the animal and human pharmaceutical sectors, leveraging core technologies such as microbial fermentation, drug coating, and DDS to develop diverse products. Its key revenue drivers include award-winning products like CTCZYME and ODF films, while the company actively manages foreign exchange risks to strengthen its global competitiveness.

Number of Employees

237people

Average Salary

46.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

23.39Industry Average 11.931.5Point

2.0x industry avg (risky)

PBR

1.07Industry Average 0.892.5Point

Higher than industry avg (caution)

ROE

4.55Industry Average 4.014.0Point

In line with industry avg

Debt Ratio

27.63Industry Average 12.430.0Point

2.2x industry avg (risky)

Trend 2023~20253.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼4.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲135.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -7.0% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
씨티씨바이오, 1분기 영업이익 46억원…전년대비 414% 증가
씨티씨바이오의 1분기 영업이익이 전년 동기 대비 414% 증가하며, 해외 수출 확대와 고마진 제품 판매로 인해 수익성이 크게 개선되었다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 3,205Won52-week high 7,45052-week low 3,205

1-month return1.0Point

1m -12.79% (falling)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-12